Disingenuous is continually referring to a phase 1 trial in healthy volunteers as a phase 1/2, even after completion!
Disingenuous is referring to an upcoming 2024 phase 3 UTI trial in recent investor presentations, even though that was clearly impossible.
Disingenuous is including graphs from previous in-vivo studies in this announcement about the phase 1 trial, even though the data is not from this trial.
Zecs is right. What was supposedly going to be a 2024 phase 3 UTI trial barely qualifies as a phase 2 - though at least we'll finally see in in action in paitents that actually have UTIs (I hope!).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)